Welcome to our dedicated page for Brainstorm Cell Therapeutics I news (Ticker: BCLI), a resource for investors and traders seeking the latest updates and insights on Brainstorm Cell Therapeutics I stock.
BrainStorm Cell Therapeutics Inc. (BCLI) generates a steady flow of news centered on its NurOwn® autologous stem cell platform for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Company press releases highlight clinical milestones, regulatory interactions, financing developments, and scientific presentations that shape the outlook for its lead investigational therapy.
News coverage frequently focuses on clinical trial progress for NurOwn, including the completed Phase 3 ALS study and preparations for the Phase 3b ENDURANCE trial under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration. Updates describe FDA clearance to initiate the Phase 3b trial, submission of an IND amendment, listing of the study on ClinicalTrials.gov, and operational steps such as site activation and manufacturing readiness.
Investors and observers will also find data-driven announcements, such as survival results from BrainStorm’s Expanded Access Program in ALS and pharmacogenomic and biomarker analyses presented at scientific meetings. These releases detail how NurOwn-treated cohorts performed relative to published ALS survival estimates and discuss factors like the UNC13A genotype and cerebrospinal fluid biomarker pathways.
Additional news items cover regulatory and community developments, including the FDA’s consideration of a Citizen Petition requesting renewed review of NurOwn data, as well as BrainStorm’s engagement with the ALS community. Financial results and capital-raising activities are reported through quarterly earnings releases and 8-K filings, alongside information about promissory and convertible promissory notes.
Stock Titan’s BCLI news page aggregates these company-issued updates and related coverage, allowing readers to follow clinical, regulatory, scientific, and financing events that may influence BrainStorm’s development trajectory. For those tracking BCLI, this page offers a single location to review the latest disclosed information on NurOwn, ALS and MS programs, manufacturing partnerships, and listing status changes.
BrainStorm Cell Therapeutics (BCLI) announced Q1 2021 financial results and significant progress in its clinical trials. The Phase 2 trial of NurOwn® for progressive multiple sclerosis achieved primary safety endpoints, showing clinically meaningful improvements compared to matched cohorts. Cash reserves stood at approximately $40 million. R&D expenses decreased to $4.3 million from $5.9 million YoY, while the net loss shrank to $6.6 million, or $0.19 per share, down from $8.1 million, or $0.32 per share, in Q1 2020. A corporate update highlights ongoing efforts in ALS treatment development and regulatory strategy.
BrainStorm Cell Therapeutics Inc. (BCLI) will hold a conference call on April 26, 2021, at 8:00 a.m. ET to disclose financial results for Q1 2021, which ended on March 31, 2021. CEO Chaim Lebovits will provide updates, followed by a Q&A session. The company focuses on cellular therapies for neurodegenerative diseases, particularly its NurOwn® technology platform, which has received FDA and EMA Orphan Drug designations for treating ALS. The Phase 3 trial for ALS has been completed, with a Phase 2 trial for MS also underway.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced positive topline data from its Phase 2 trial of NurOwn® for progressive multiple sclerosis (MS). The trial met its primary endpoint for safety and demonstrated improvements in secondary outcomes, including neurologic function and cognition. Of the 20 enrolled patients, 16 completed the study, with significant enhancements in measures like the timed 25-foot walk test and cognitive processing tests. The results suggest NurOwn® has potential as a therapeutic option for progressive MS, urging further evaluations and data presentation at scientific meetings.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021. Dr. Stacy Lindborg, EVP and head of Global Clinical Research, will present a corporate update at 8:40 AM Eastern Time. A live webcast of the presentation can be accessed via the provided link. The company focuses on developing adult stem cell therapies for neurodegenerative diseases. Caution is advised regarding forward-looking statements about clinical trials and financial requirements.
BrainStorm Cell Therapeutics (BCLI) announced that it received initial feedback from the FDA regarding the clinical data from its NurOwn ALS Phase 3 trial. The FDA indicated that the current data does not meet the criteria needed for a Biologics License Application (BLA). However, the FDA's stance allows BrainStorm to still pursue a BLA submission. The company, well-funded with over $40M in cash, plans to consult with ALS experts and stakeholders before making a decision on the BLA submission. They aim to analyze data further and communicate findings in a peer-reviewed publication.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced a successful Type C meeting with the FDA regarding manufacturing modifications for NurOwn®. The meeting provided actionable guidance on transitioning to a semi-automated manufacturing process, aimed at increasing capacity and reducing manufacturing risks. The company plans to finalize a comparability plan and conformance batches for NurOwn® while leveraging FDA feedback. This development marks a positive step in BrainStorm's efforts to advance the regulatory submission for NurOwn®, which seeks to treat neurodegenerative diseases like ALS.
BrainStorm Cell Therapeutics (BCLI) announced significant financial results for 2020, marked by the completion of its pivotal Phase 3 ALS trial for NurOwn®. While the trial did not achieve statistical significance in its primary endpoint, analyses indicate a clinically meaningful effect. Financially, cash and liquidity stood at approximately $45 million at the start of 2021, a substantial increase from $0.6 million in 2019. The net loss for 2020 rose to $31.8 million from $23.3 million in 2019. The company aims to advance its clinical programs in multiple sclerosis and Alzheimer's disease in 2021.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) will hold a conference call on February 4, 2020, at 8:00 a.m. ET to discuss its financial results for Q4 and the fiscal year ended December 31, 2020. The call will include an update from CEO Chaim Lebovits, followed by a Q&A session. Key developments include the completion of a Phase 3 trial for ALS and an ongoing Phase 2 trial for progressive MS, with topline results expected in Q1 2021. The company is also in discussions with the FDA regarding regulatory pathways for NurOwn® approval.
BrainStorm Cell Therapeutics (BCLI) announced the publication of a preclinical study on NurOwn® exosomes in the journal Stem Cell and Research Therapy. The study demonstrated that the intratracheal administration of NurOwn® exosomes led to significant reductions in lung disease severity in a mouse model of ARDS, a condition often associated with COVID-19. Results showed superior improvements over naïve MSC-derived exosomes in various ARDS markers. BrainStorm aims to explore the therapeutic potential of this approach while advancing NurOwn® towards regulatory approval for ALS.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) reported significant advancements in 2020, highlighted by the completion of the Phase 3 ALS clinical trial for NurOwn®. Although the primary efficacy endpoint did not achieve statistical significance, pre-specified subgroup analyses demonstrated a clinically meaningful treatment effect. The company is engaging with the FDA on regulatory pathways for NurOwn's approval. Additionally, a new Expanded Access Program has been initiated for ALS patients. With over $40 million in cash and ongoing manufacturing capabilities expansion, BrainStorm aims to address the unmet needs in neurodegenerative diseases.